Trial reportArteriosclerosis, thrombosis, and vascular biology2025
Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study.
Trial report in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02978040 (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial
TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2017 to 2019Enrolled122ConditionsCoronary Artery Disease, STEMI - ST Elevation Myocardial InfarctionArmsCangrelor, Tirofiban, Prasugrel
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Pietro Minuz *Department of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy.ORCID 0000-0001-5450-2186
Alejandro Giorgetti *Department of Biotechnology (A.G., R.P.R., F. Baldessari), University of Verona, Italy.
Alessandra MeneguzziDepartment of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy.ORCID 0000-0003-4269-9924
Francesco TausDepartment of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy.ORCID 0000-0003-4728-6686
Rui P RibeiroDepartment of Biotechnology (A.G., R.P.R., F. Baldessari), University of Verona, Italy.ORCID 0000-0001-9939-2013
Filippo BaldessariDepartment of Biotechnology (A.G., R.P.R., F. Baldessari), University of Verona, Italy.ORCID 0000-0003-1780-2723
Giuseppe GargiuloDepartment of Advanced Biomedical Sciences, University Federico II of Naples, Italy (G.G.).ORCID 0000-0003-4395-6742
Felice GragnanoDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Caserta, Italy (F.G.).ORCID 0000-0002-6943-278X
Antonio LandiCardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., M.V.).
Marco CastelliDepartment of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy.ORCID 0000-0002-7542-601X
Rossella GottardoDepartment of Diagnostics and Public Health, Unit of Forensic Medicine (F. Taus, R.G., F. Bortolotti, F. Tagliaro), University of Verona, Italy.ORCID 0000-0001-5997-1723
Federica BortolottiDepartment of Diagnostics and Public Health, Unit of Forensic Medicine (F. Taus, R.G., F. Bortolotti, F. Tagliaro), University of Verona, Italy.ORCID 0000-0002-9568-4585
Giuseppe VerlatoDepartment of Diagnostics and Public Health, Unit of Epidemiology and Medical Statistics (G.V.), University of Verona, Italy.ORCID 0000-0001-5262-8818
Cristiano FavaDepartment of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy.ORCID 0000-0002-8910-7378
Marco CattaneoFondazione Arianna Anticoagulazione, Bologna, Italy (M. Cattaneo).ORCID 0000-0002-7343-4534
Franco TagliaroDepartment of Diagnostics and Public Health, Unit of Forensic Medicine (F. Taus, R.G., F. Bortolotti, F. Tagliaro), University of Verona, Italy.ORCID 0000-0002-2187-9128
Marco ValgimigliCardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., M.V.).ORCID 0000-0002-4353-7110
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundPrasugrel is converted into prasugrel active metabolite (PAM; R-138727) through the cytochrome P450-mediated conversion of an intermediate metabolite (PIM; R-95913). It is unknown whether PIM exerts any biological function. The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients With ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) showed that chewed prasugrel does not improve bioactivity, in spite of accelerated PAM kinetics.
methodsPIM and PAM pharmacokinetics were assessed by mass spectrometry in blood samples collected from ST-segment-elevation myocardial infarction patients randomized to chewed (n=17) or integral (n=15) 60 mg prasugrel. The ex vivo and in vitro effects of PAM and PIM were assessed on ADP-induced platelet activation. The binding sites of PIM and PAM were investigated by molecular dynamics simulation.
resultsChewed prasugrel was associated with higher PIM levels compared with integral prasugrel: PIM median area under the curve (25-75 p): 73 (41.5-92.0) versus 33 (0.0-50.0) ng·h/mL (
conclusionsPIM negatively interferes with PAM, thereby reducing its inhibitory activity, likely competing at the P2Y REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02978040. URL: https://www.clinicaltrialsregister.eu; Unique identifier: EudraCT 2017-001065-24.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study. · full record | Socratic